Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …

Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …

Over the last decades, the concept of precision medicine has dramatically renewed the field
of medical oncology; the introduction of patient-tailored therapies has significantly improved …

Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

The inherent molecular heterogeneity of metastatic tumors and the ability of cancer
genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of …

The analysis of circulating tumor cells (CTCs) is an outstanding tool to provide insights into
the biology of metastatic cancers, to monitor disease progression and with potential for use …

Single‐cell RNA sequencing (scRNA‐seq) is a novel technology that allows transcriptomic
analyses of individual cells. During the past decade, scRNA‐seq sensitivity, accuracy, and …

Importance The choice between chemotherapy and endocrine therapy as first-line treatment
for hormone receptor–positive, ERBB2 (also known as HER2)-negative metastatic breast …

Recent technological advances have enabled the detection and detailed characterization of
circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) in blood samples from …